[go: up one dir, main page]

NO20065380L - Anvendelse av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmorsyrehydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer. - Google Patents

Anvendelse av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmorsyrehydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer.

Info

Publication number
NO20065380L
NO20065380L NO20065380A NO20065380A NO20065380L NO 20065380 L NO20065380 L NO 20065380L NO 20065380 A NO20065380 A NO 20065380A NO 20065380 A NO20065380 A NO 20065380A NO 20065380 L NO20065380 L NO 20065380L
Authority
NO
Norway
Prior art keywords
diisopropylamino
phenylpropyl
spasmogenic
medicament
diseases
Prior art date
Application number
NO20065380A
Other languages
English (en)
Other versions
NO332637B1 (no
Inventor
Claus Meese
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7929277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065380(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20065380L publication Critical patent/NO20065380L/no
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO332637B1 publication Critical patent/NO332637B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

Anvendelse av R-(+)-2-(3 -diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmørsyre- hydrogenfimiarat eller den krystallinske form av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4- hydroksymetyl-fenylisosmørsyrehydrogenfimiarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer.
NO20065380A 1999-11-16 2006-11-22 Anvendelse av R-(+)-2-(3-diisopropylamino-1-fenylpropyl)-4-hydroksymetyl-fenylisosmørsyreester- hydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer og farmasøytisk formulering derav NO332637B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19955190A DE19955190A1 (de) 1999-11-16 1999-11-16 Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
PCT/EP2000/011309 WO2001035957A1 (de) 1999-11-16 2000-11-15 Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen

Publications (2)

Publication Number Publication Date
NO20065380L true NO20065380L (no) 2002-05-15
NO332637B1 NO332637B1 (no) 2012-11-26

Family

ID=7929277

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20022314A NO323920B1 (no) 1999-11-16 2002-05-15 Stabile forbindelser av nye derivater av 3,3-difenylpropylaminer, fremgangsmåte for fremstilling derav og nye mellomprodukter
NO20065380A NO332637B1 (no) 1999-11-16 2006-11-22 Anvendelse av R-(+)-2-(3-diisopropylamino-1-fenylpropyl)-4-hydroksymetyl-fenylisosmørsyreester- hydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer og farmasøytisk formulering derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20022314A NO323920B1 (no) 1999-11-16 2002-05-15 Stabile forbindelser av nye derivater av 3,3-difenylpropylaminer, fremgangsmåte for fremstilling derav og nye mellomprodukter

Country Status (30)

Country Link
US (1) US6858650B1 (no)
EP (3) EP1690536B1 (no)
JP (6) JP4083431B2 (no)
KR (2) KR100536095B1 (no)
CN (1) CN1215045C (no)
AT (3) ATE395056T1 (no)
AU (1) AU778132B2 (no)
BR (1) BRPI0015610C1 (no)
CA (1) CA2389749C (no)
CY (2) CY1106204T1 (no)
CZ (2) CZ302497B6 (no)
DE (5) DE19955190A1 (no)
DK (3) DK1481964T3 (no)
EA (1) EA005588B1 (no)
ES (3) ES2236032T7 (no)
GE (1) GEP20084430B (no)
HK (1) HK1045148B (no)
HU (2) HU228197B1 (no)
IL (2) IL149567A0 (no)
IS (2) IS2124B (no)
MX (1) MXPA02004603A (no)
NO (2) NO323920B1 (no)
NZ (1) NZ519230A (no)
PL (1) PL201422B1 (no)
PT (3) PT1230209E (no)
SI (3) SI1230209T1 (no)
SK (3) SK287430B6 (no)
UA (2) UA73324C2 (no)
WO (1) WO2001035957A1 (no)
ZA (1) ZA200203315B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
KR100647068B1 (ko) 2005-09-15 2006-11-23 하나제약 주식회사 라세믹ｎ,ｎ-디이소프로필-3-(2-히드록시-5-메틸페닐)-3-페닐프로판아민의 제조방법
ATE480531T1 (de) * 2006-05-24 2010-09-15 Pfizer Ltd Verfahren zur herstellung von benzopyran-2- olderivaten
EP1940774B1 (en) * 2006-05-31 2014-03-05 Schwarz Pharma Ltd. New synthesis of substituted hydroxymethyl phenols
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
DE602007008389D1 (de) * 2006-06-09 2010-09-23 Schwarz Pharma Ltd Synthese von phenolischen estern von hydroxymethylphenolen
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
PE20120476A1 (es) * 2006-06-09 2012-04-20 Sanol Arznei Schwarz Gmbh Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
PL2027103T3 (pl) 2006-06-12 2014-12-31 Ucb Pharma Gmbh Nowe, chiralne związki pośrednie, sposób ich wytwarzania i ich zastosowanie w wytwarzaniu tolterodyny, fesoterodyny lub ich aktywnych metabolitów
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
US20100297241A1 (en) * 2007-10-01 2010-11-25 Actavis Group Ptc Ehf Amorphous Fesoterodine Fumarate
WO2009122303A2 (en) * 2008-04-04 2009-10-08 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
US20110171274A1 (en) * 2008-07-21 2011-07-14 Actavis Group Ptc Ehf Fesoterodine Substantially Free of Dehydroxy Impurity
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
WO2010130392A1 (de) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfesoterodin in form eines weinsäuresalzes
IT1394219B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
IT1394217B1 (it) * 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
EP2459520A1 (en) 2009-09-03 2012-06-06 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Crystalline forms of fesoterodine fumarate and fesoterodine base
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20110124903A1 (en) * 2009-11-20 2011-05-26 Actavis Group Ptc Ehf Solid state forms of fesoterodine intermediates
IT1397521B1 (it) * 2009-12-21 2013-01-16 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze.
IT1397920B1 (it) * 2010-02-08 2013-02-04 Dipharma Francis Srl Forma cristallina di fesoterodina fumarato e procedimento per la sua preparazione
EP2549985A1 (en) 2010-03-22 2013-01-30 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US20110282094A1 (en) * 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
WO2011158257A1 (en) 2010-06-18 2011-12-22 Panacea Biotec Ltd Preparation process of fesoterodine and intermediates
US9012678B2 (en) * 2010-08-25 2015-04-21 Cadila Healthcare Limited Processes for the preparation of fesoterodine
IT1403094B1 (it) * 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
WO2012098560A2 (en) * 2011-01-17 2012-07-26 Msn Laboratories Limited Process for the preparation of muscarinic receptor antagonist
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
JP6234999B2 (ja) 2012-05-04 2017-11-22 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． 光学的に活性な３，３−ジフェニルプロピルアミンを調製するための方法
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
TR201721437A2 (tr) 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
WO2022090235A1 (en) * 2020-10-27 2022-05-05 Wella Germany Gmbh 2-methoxymethyl-p-phenylenediamine in cosmetic grade quality

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75395B (no) * 1980-11-14 1984-07-13 Lilly Co Eli
IL66831A0 (en) * 1981-10-05 1982-12-31 Kefalas As Indane derivatives
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
EP0445749B1 (en) * 1990-03-08 1996-07-10 Fujisawa Pharmaceutical Co., Ltd. N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments
JPH0483431A (ja) * 1990-07-26 1992-03-17 Seiko Epson Corp 選択呼出受信機
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen

Also Published As

Publication number Publication date
HU227608B1 (en) 2011-09-28
JP5717824B2 (ja) 2015-05-13
JP4083431B2 (ja) 2008-04-30
DE19955190A1 (de) 2001-06-21
ZA200203315B (en) 2003-09-23
AU2666701A (en) 2001-05-30
HU0900587D0 (en) 2009-11-30
IS6351A (is) 2002-04-19
SK288384B6 (sk) 2016-08-01
EP1481964B1 (de) 2006-08-23
HUP0204034A2 (hu) 2003-03-28
JP2007137895A (ja) 2007-06-07
MXPA02004603A (es) 2004-09-10
BRPI0015610B1 (pt) 2016-04-19
PT1230209E (pt) 2005-05-31
EP1230209B3 (de) 2011-10-05
WO2001035957A1 (de) 2001-05-25
DK1230209T3 (da) 2005-05-30
AU778132B2 (en) 2004-11-18
BR0015610B8 (pt) 2017-10-31
JP2011148824A (ja) 2011-08-04
DK1690536T3 (da) 2008-09-01
DK1481964T3 (da) 2006-11-27
EA200200511A1 (ru) 2002-10-31
EP1230209A2 (de) 2002-08-14
ES2303708T3 (es) 2008-08-16
CN1390194A (zh) 2003-01-08
ATE395056T1 (de) 2008-05-15
EA005588B1 (ru) 2005-04-28
EP1690536A2 (de) 2006-08-16
BRPI0015610C1 (pt) 2021-05-25
ATE286872T1 (de) 2005-01-15
HK1045148B (zh) 2005-05-06
JP5290351B2 (ja) 2013-09-18
PL201422B1 (pl) 2009-04-30
NO20022314D0 (no) 2002-05-15
CY1106204T1 (el) 2011-06-08
NO332637B1 (no) 2012-11-26
SI1481964T1 (sl) 2006-12-31
ATE337293T1 (de) 2006-09-15
WO2001035957A8 (de) 2001-06-21
ES2236032T3 (es) 2005-07-16
PT1481964E (pt) 2006-12-29
SK6572002A3 (en) 2002-12-03
CZ20021343A3 (cs) 2002-09-11
SI1230209T1 (en) 2005-06-30
BR0015610A (pt) 2002-07-30
PL356766A1 (en) 2004-07-12
IL149567A (en) 2007-08-19
NO323920B1 (no) 2007-07-23
UA73324C2 (uk) 2005-07-15
KR20050100711A (ko) 2005-10-19
HK1095736A1 (en) 2007-05-18
EP1690536A3 (de) 2006-08-23
DE50015163D1 (de) 2008-06-26
CZ302967B6 (cs) 2012-01-25
CZ302497B6 (cs) 2011-06-15
SK287430B6 (sk) 2010-09-07
EP1481964A1 (de) 2004-12-01
WO2001035957A3 (de) 2001-12-27
CA2389749C (en) 2009-03-31
SI1690536T1 (sl) 2008-08-31
NO20022314L (no) 2002-05-15
SK288185B6 (sk) 2014-04-02
US6858650B1 (en) 2005-02-22
GEP20084430B (no) 2008-07-25
DE50013365D1 (de) 2006-10-05
HK1067114A1 (en) 2005-04-01
DE29923134U1 (de) 2000-06-29
IS8382A (is) 2006-03-29
NZ519230A (en) 2004-11-26
IS2124B (is) 2006-07-14
HK1045148A1 (en) 2002-11-15
JP2003514018A (ja) 2003-04-15
EP1230209B1 (de) 2005-01-12
KR20020059744A (ko) 2002-07-13
JP5503393B2 (ja) 2014-05-28
JP5650924B2 (ja) 2015-01-07
UA77322C2 (en) 2006-11-15
CY1110389T1 (el) 2015-04-29
DE50009239D1 (de) 2005-02-17
CA2389749A1 (en) 2001-05-25
JP2010180242A (ja) 2010-08-19
IS2673B (is) 2010-09-15
CN1215045C (zh) 2005-08-17
ES2270240T3 (es) 2007-04-01
EP1690536B1 (de) 2008-05-14
HU228197B1 (en) 2013-01-28
ES2236032T7 (es) 2012-06-14
KR100536095B1 (ko) 2005-12-12
KR100563149B1 (ko) 2006-03-21
JP2010180243A (ja) 2010-08-19
IL149567A0 (en) 2002-11-10
PT1690536E (pt) 2008-07-14
HUP0204034A3 (en) 2004-12-28
HUP0900587A3 (en) 2010-04-28
JP2014111589A (ja) 2014-06-19

Similar Documents

Publication Publication Date Title
NO20065380L (no) Anvendelse av R-(+)-2-(3-diisopropylamino-l-fenylpropyl)-4-hydroksymetyl-fenylisosmorsyrehydrogenfumarat for fremstilling av et medikament for behandling av urininkontinens og andre spasmogeniske sykdommer.
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
IL139230A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds to the upper respiratory tract and/or the ear
PL367277A1 (en) Methods of making sustained release formulations of oxymorphone related applications
DK1235826T3 (da) Quinuclidinacrylamider
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
HUP9800794A2 (hu) (S)-oxi-butinin és (S)-dezetil-oxi-butinin alkalmazása vizelet inkontinencia kezelésére alkalmazható gyógyszerkészítmények előállítására és a vegyületek előállítása
EE05025B1 (et) Fumaarhappe derivaadid kasutamiseks transplantaadivastase reaktsiooni raviks
CA2403687A1 (en) Surgical articles
NZ545506A (en) Therapeutic agents useful for treating pain
SE9803518D0 (sv) Novel compounds
WO2001024783A3 (de) Verwendung von (+)-tramadol, o-demethyltramadol bzw. (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol bzw. (+)-o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO982989L (no) Anvendelse av inhibitorer av den cellulµre Na+/H+-utbytteren (NHE) for fremstilling av et medikament for respiratorstimulering
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
SE9803773D0 (sv) Compounds
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
NO944407D0 (no) Alkoholer som kalium-kanalåpnere og ved behandling av urin-inkontinens
GB9227123D0 (en) Method
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NZ334571A (en) Pharmaceutical composition comprising 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid for treating diseases induced by respiratory syncytial virus
SE9903611D0 (sv) Novel compounds III
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: PFIZER INC., US

Owner name: UCB PHARMA GMBH, DE

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

MK1K Patent expired